文档介绍：中国现代医生 年 月第 卷第 期
2021 12 59 36 tal from May 2014 to May 2019 were retrospectively patients with progressive stroke were treated with
double-antibody as the observation group, and 150 patients with progressive stroke were treated with monoclonal anti鄄
body as the control the above treatment, NIHSS score and mRs score, clinical efficacy and complication
Results
rate were observed. Compared with the control group, the NIHSS score and mRs score in the observation group
of 14 d of admission were significantly lower than those in the control group,and the differences were statistically signif鄄
t P Conclusion
icant( =, , <). Double-antibody therapy is superior to monoclonal antibody therapy for
progressive stroke.
[Key words]
Progressive stroke; Monoclonal antibody therapy; Double-antibody therapy; National institutes of health
stroke scale; Modified rankin scale
脑卒中具有发病率高 复发率高 致残率高和死 评分增加 分以上[2] 其属于难治性脑血管病
尧 尧 NIHSS 2 遥 袁
亡率高等特点 在全球范围内 脑卒中已成为人类死 发病率约为 会使卒中的病死率